Modality
ADC
MOA
GLP-1/GIP
Target
SOS1
Pathway
Complement
HCC
Development Pipeline
Preclinical
~May 2010
→ ~Aug 2011
Phase 1
~Nov 2011
→ ~Feb 2013
Phase 2
~May 2013
→ ~Aug 2014
Phase 3
~Nov 2014
→ ~Feb 2016
NDA/BLA
~May 2016
→ ~Aug 2017
Approved
Nov 2017
→ Jan 2031
ApprovedCurrent
NCT04705648
2,824 pts·HCC
2019-10→2031-01·Recruiting
NCT07795322
2,796 pts·HCC
2021-03→2029-08·Active
NCT06776448
2,979 pts·HCC
2017-11→TBD·Not yet recruiting
8,599 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2029-08-183.4y awayPh3 Readout· HCC
2031-01-054.8y awayPh3 Readout· HCC
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
Approved
Not yet…
Approved
Recruit…
Approved
Active
Catalysts
Ph3 Readout
2029-08-18 · 3.4y away
HCC
Ph3 Readout
2031-01-05 · 4.8y away
HCC
RecruitingActiveNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04705648 | Approved | HCC | Recruiting | 2824 | CR |
| NCT07795322 | Approved | HCC | Active | 2796 | CR |
| NCT06776448 | Approved | HCC | Not yet recr... | 2979 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Fixaosocimab | TG Therapeutics | Phase 2/3 | SOS1 | |
| Zanurapivir | Immunocore | Phase 1 | SOS1 |